OCGN earnings analysis
What we found in OCGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ocugen, Inc. reported Q1 2026 earnings with substantial revenue of $1,533,000, significantly exceeding expectations of $526,512, although the EPS came in at -$0.06, slightly below the forecast of -$0.05. The company incurred a net loss of $19.2 million, an increase compared to $15.4 million in the previous year, highlighting ongoing operational expenses despite revenue growth.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Beat
- Total revenue reached $1,533,000, beating estimates by 1.91x, which is a significant improvement from the estimated revenue of $526,512.
- Increased R&D Spending
- Research and development expenses increased to $11,255,000 from $9,529,000, driven by clinical activities.
- Improved Financing Position
- Completed a private offering of $115 million in convertible senior notes, enhancing liquidity.
- Higher Operating Expenses
- Total operating expenses rose to $19,372,000, up $3,390,000 from the prior year, mainly due to staffing costs.
- Cash Position
- Cash and cash equivalents stood at $31.9 million as of March 31, 2026, providing some buffer for upcoming expenditures.
- Debt Management
- Debt level was reported at approximately $29.2 million, with new convertible notes set to address some existing obligations.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Net Loss
- Net loss for Q1 2026 was $19.2 million, up from $15.4 million in Q1 2025, indicating worsening financial performance.
- Operational Cash Burn
- Cash used in operating activities totaled $21.8 million, showing a higher cash burn rate compared to $19.4 million in the prior year.
- Dependency on Future Funding
- The company anticipates requiring additional funding due to ongoing operational losses and is subject to risks associated with raising capital.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
- Gross margin
- 100.0%
What they said about what is next.
Future outlook conditions remain uncertain; specific numeric guidance deferred to earnings press release/call.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OCGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever